Late-onset NMOSD patients see worse recovery, faster disability
A study linked late-onset neuromyelitis optica spectrum disorder to worse recovery from relapses and faster disability progression.| Neuromyelitis News
A study linked late-onset neuromyelitis optica spectrum disorder to worse recovery from relapses and faster disability progression.| Neuromyelitis News
Uplizna reduces several subsets of immune B-cells that are linked to relapses in people with neuromyelitis optica spectrum disorder, data show.| Neuromyelitis News
Attacks marked by spinal cord inflammation significantly increase the chance of worse disability in NMOSD and MOGAD, per a study.| Neuromyelitis News
A new AI model that analyzes images of the eye can help accurately identify neuromyelitis optica spectrum disorder (NMOSD), a study shows.| Neuromyelitis News
Most neuromyelitis optica spectrum disorder patients experience impaired sleep and worse disability relative to healthy people, per a study.| Neuromyelitis News
The findings support the idea that gut microbiota and the gut-brain axis factor in NMOSD, and that approaches like GV-971 may help patients.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
A family of molecules that can influence immune activity may spot neuromyelitis optica spectrum disorder in people, serving as biomarkers.| Neuromyelitis News
Nearly all clinicians (88%) in a U.S. survey have prescribed approved NMOSD treatments for their patients with anti-AQP4 antibodies.| Neuromyelitis News
Infections of shingles and cold sores were found to be associated with AQP4 antibody-positive neuromyelitis optica spectrum disorder.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
NMOSD may begin to manifest as hard-to-treat nausea, vomiting, or hiccups — a condition called area postrema syndrome — delaying a diagnosis.| Neuromyelitis News
Rituximab was more efficient at preventing relapses than oral immunosuppressive therapies in a racially diverse group of people with NMOSD.| Neuromyelitis News
Three weeks of low-dose rituximab was found to prevent relapses and disability progression in NMOSD patients, without serious side effects.| Neuromyelitis News
Enspryng (satralizumab-mwge) is an injection therapy approved for adults with neuromyelitis optica spectrum disorder (NMOSD).| Neuromyelitis News
Sex ratio and age at onset among NMOSD patients are influenced by the proportion of cases with anti-AQP4 antibodies, a review study found.| Neuromyelitis News
Neuromyelitis optica spectrum disorder patients whose first symptoms affect the brainstem are often misdiagnosed and have more relapses, a study finds.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
